WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Oklo_Powerhouse_3_Datacenter

Mid Cap

News

Movers

Trading Ideas

$BTC

AMZN

CLSK

IONQ

LBPH

OKLO

WOLF

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?

Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?


Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. The company is generating significant interest from

Wave Life Sciences Rockets 70% on Historic RNA Editing Success

Santa,Clara,,Ca, - ,Usa,-,March,26,,2019:,Cisco

Upgrades

Markets

Analyst Ratings

CSCO

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences Ltd

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation)
Proof-of-concept clinical data from INLIGHT are expected in 2025

Biotech

General

Wave Life Sciences Initiates Phase 1 INLIGHT Clinical Trial Of WVE-007 In Obesity

Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with the potential to treat well over 100 million patients
CTAs submitted for Phase 1 INLIGHT clinical trial of WVE-007, a novel, long-acting, muscle-sparing GalNAc-siRNA approach for obesity targeting INHBE grounded in human genetics; proof-of-concept clinical data expected in 2025
Pioneering entirely new therapeutic field of RNA editing and building on positive WVE-006 proof-of mechanism clinical data; expect multidose AATD data, new preclinical data from hepatic and extra-hepatic RNA editing programs and candidate selections in 2025
Expect feedback from regulators and 48-week FORWARD-53 data for WVE-N531 in DMD in 1Q 2025; positive interim data demonstrated highly consistent dystrophin expression and best-in-class muscle delivery
Advancing WVE-003 – only allele-selective treatment for HD; planning underway for potentially registrational Phase 2/3 study with caudate atrophy as a primary endpoint and IND submission expected 2H 2025
Well-capitalized with expected runway into 2027

Guidance

Wave Life Sciences Announces 2025 Plans, Phase 1 INLIGHT Trial For Obesity Target WVE-007; RNA Editing Advancements With WVE-006; Regulatory Feedback And 48-Week Data For WVE-N531 In DMD Expected Q1 2025; Phase 2/3 Study For HD Treatment WVE-003 In Planning; Capital Runway To 2027

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration
WVE-007 is Wave's first siRNA program to enter clinical development and uses best-in-class oligonucleotide chemistry and GalNAc delivery
Wave expects to initiate the first-in-human study of WVE-007 in 1Q 2025
CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the submission of its first clinical trial application (CTA) for WVE-007 in obesity. WVE-007 is an investigational GalNAc-conjugated small interfering RNA (siRNA) designed to silence Inhibin&nbsp;βE (INHBE) gene expression, which would induce fat burning (lipolysis) to decrease body weight without impacting muscle mass. Wave expects CTA approval and initiation of the first-in-human study of WVE-007 in the first quarter of 2025.

Wave Life Sciences Announces Submission Of First Clinical Trial Application For WVE-007 In Obesity

Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Outperform and raises the price target from $19 to $22.

Price Target

Mizuho Maintains Outperform on WAVE Life Sciences, Raises Price Target to $22

HC Wainwright &amp; Co. analyst Andrew Fein reiterates WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and maintains $22 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on WAVE Life Sciences, Maintains $22 Price Target

Truist Securities analyst Joon Lee maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and raises the price target from $17 to $36.

Truist Securities Maintains Buy on WAVE Life Sciences, Raises Price Target to $36

WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.28) by 67.86 percent.

Earnings

Earnings Misses

WAVE Life Sciences Q3 2024 GAAP EPS $(0.47) Misses $(0.28) Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect WAVE Life Sciences to report an earnings per share (EPS) of $-0.29.
Anticipation surrounds WAVE Life Sciences's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.04, leading to a 5.75% drop in the share price on the subsequent day.
Here's a look at WAVE Life Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.21</td>
<td>-0.21</td>
<td>-0.23</td>
<td>-0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.25</td>
<td>-0.24</td>
<td>-0.15</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-2.0%</td>
<td>8.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731333748_0.png" alt="eps graph" />
<h3>Tracking WAVE Life Sciences's Stock Performance</h3>
Shares of WAVE Life Sciences were trading at $16.44 as of November 08. Over the last 52-week period, shares are up 202.21%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/WVE/earnings">To track all earnings releases for WAVE Life Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: WAVE Life Sciences's Earnings Preview

B. Riley Securities analyst Madison El-Saadi maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and raises the price target from $19 to $22.

B. Riley Securities Maintains Buy on WAVE Life Sciences, Raises Price Target to $22

WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s
Recent proof-of-mechanism data for WVE-006 unlocked Wave's best-in-class RNA editing capabilities; three new wholly owned RNA editing programs targeting PNPLA3, LDLR and APOB are first-in-class approaches to address significant unmet needs in cardiometabolic diseases
Wave plans to have five GalNAc-RNA editing or GalNAc-siRNA programs in the clinic by 2026
Wave's clinically validated platform continues to lead on the improvement of intracellular delivery using novel chemistry, including PN backbone chemistry modifications
&nbsp;

Wave Life Sciences Highlights Growing Pipeline At Research Day

RBC Capital analyst Luca Issi maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Sector Perform and raises the price target from $7 to $15.

RBC Capital Maintains Sector Perform on WAVE Life Sciences, Raises Price Target to $15

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Oklo Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) stock gained 99.23% last week. Nuclear-linked stocks gained after Amazon Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) AWS <a href="https://www.benzinga.com//node/41358363" target="_blank" rel="noreferrer noopener">announced plans to invest</a> over $500 million in nuclear power.</li>
<li>Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) shares jumped 67.35% after the company achieved its first-ever therapeutic RNA editing in humans from its RestorAATion-2 trial of WVE-006 for <a href="https://www.benzinga.com//node/41359843" target="_blank" rel="noreferrer noopener">Alpha-1 antitrypsin deficiency</a>. Several analysts raised the price <a href="https://www.benzinga.com/quote/wve/analyst-ratings" target="_blank" rel="noreferrer noopener">target on the stock</a>.</li>
<li>Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) gained 52.21% after the company announced it would be acquired by Lundbeck <a href="https://www.benzinga.com//node/41313129" target="_blank" rel="noreferrer noopener">for $60 per share in cash</a>.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares rocketed 42.44% after signing a non-binding preliminary memorandum of terms for up to $750 million in proposed direct funding under <a href="https://www.benzinga.com//node/41339603" target="_blank" rel="noreferrer noopener">the CHIPS and Science Act</a>.</li>
<li>CleanSpark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) stock upped 34.10% last week after Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com//node/41386011" target="_blank" rel="noreferrer noopener">rose above $67,000</a>.</li>
<li>Telephone and Data Systems, Inc. (NYS: TDS) soared 26.03% after the company announced its subsidiary, United State Cellular Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>), <a href="https://www.benzinga.com//node/41403665" target="_blank" rel="noreferrer noopener">selling select spectrum licenses</a> in the AWS and PCS bands.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares increased 15.31%. The company will report third-quarter <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">financial results on November 6</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com//node/41418999" target="_blank" rel="noreferrer noopener">NIO, ASML, And CVS Health Are Among Top 10 Large Cap Losers Last Week (Oct 14-18): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41418879/coinbase-united-airlines-and-sofi-tech-are-among-top-11-large-cap-gainers-last-week-oct-14-18-are-" target="_blank" rel="noreferrer noopener">Coinbase, United Airlines And Sofi Tech Are Among Top 11 Large Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?</a></li>
</ul>
Photo Courtesy of Oklo

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587639df5064ed0001400135/david-manthey">Baird analyst David Manthey</a> upgraded the rating for W.W. Grainger, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) from Neutral to Outperform and raised the price target from $975 to $1,230. Grainger shares closed at $1,085.57 on Tuesday. <a href="https://www.benzinga.com/quote/GWW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst David Begleiter upgraded Westlake Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) from Underperform to Neutral and boosted the price target from $151 to $159. Westlake shares closed at $141.80 on Tuesday. <a href="https://www.benzinga.com/quote/WLK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Atif Malik upgraded the rating for Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Neutral to Buy and increased the price target from $52 to $62. Cisco shares closed at $54.08 on Tuesday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cleveland Research upgraded the rating for SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) from Neutral to Buy. SAP shares closed at $229.52 on Tuesday. <a href="https://www.benzinga.com/quote/SAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Steven Seedhouse upgraded Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) from Outperform to Strong Buy and increased the price target from $13 to $22. WAVE Life Sciences shares closed at $8.56 on Tuesday. <a href="https://www.benzinga.com/quote/WVE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CSCO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png" alt="" class="wp-image-599072" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-768x388.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130.png 1297w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:<a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h">United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday</a></li>
</ul>

Raymond James analyst Steven Seedhouse upgrades WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) from Outperform to Strong Buy and raises the price target from $13 to $22.

Raymond James Upgrades WAVE Life Sciences to Strong Buy, Raises Price Target to $22

Wells Fargo analyst Tiago Fauth maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Overweight and raises the price target from $11 to $22.

Wells Fargo Maintains Overweight on WAVE Life Sciences, Raises Price Target to $22

Leerink Partners analyst Mani Foroohar maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Outperform and raises the price target from $20 to $22.

Leerink Partners Maintains Outperform on WAVE Life Sciences, Raises Price Target to $22

Whales with a lot of money to spend have taken a noticeably bullish stance on WAVE Life Sciences.
Looking at options history for WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 46% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $251,490 and 10, calls, for a total amount of $481,968.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $7.5 to $15.0 for WAVE Life Sciences during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for WAVE Life Sciences options trades today is 608.71 with a total volume of 10,303.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for WAVE Life Sciences's big money trades within a strike price range of $7.5 to $15.0 over the last 30 days.
<h3>WAVE Life Sciences Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729097158_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WVE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.15</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$12.50</td>
<td>$170.0K</td>
<td>1</td>
<td>1.0K</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.5</td>
<td>$1.95</td>
<td>$2.0</td>
<td>$15.00</td>
<td>$84.8K</td>
<td>3</td>
<td>1.9K</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.9</td>
<td>$7.5</td>
<td>$7.7</td>
<td>$7.50</td>
<td>$77.0K</td>
<td>510</td>
<td>111</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.7</td>
<td>$7.4</td>
<td>$7.5</td>
<td>$7.50</td>
<td>$75.0K</td>
<td>510</td>
<td>212</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.9</td>
<td>$5.6</td>
<td>$5.67</td>
<td>$7.50</td>
<td>$56.9K</td>
<td>1.3K</td>
<td>114</td>
</tr>
</tbody>
</table>

<h3>About WAVE Life Sciences</h3>
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
In light of the recent options history for WAVE Life Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>WAVE Life Sciences's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 13,020,486, the WVE's price is up by 74.92%, now at $14.97. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 22 days.</li>
</ul>
<h3>Professional Analyst Ratings for WAVE Life Sciences</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $14.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on WAVE Life Sciences with a target price of $7. 
&#x2A; An analyst from B. Riley Securities has revised its rating downward to Buy, adjusting the price target to $11. 
&#x2A; Maintaining their stance, an analyst from B. Riley Securities continues to hold a Buy rating for WAVE Life Sciences, targeting a price of $19. 
&#x2A; An analyst from JP Morgan has revised its rating downward to Overweight, adjusting the price target to $13. 
&#x2A; An analyst from HC Wainwright &amp; Co. has decided to maintain their Buy rating on WAVE Life Sciences, which currently sits at a price target of $22. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for WAVE Life Sciences with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Looking At WAVE Life Sciences's Recent Unusual Options Activity

Press Releases

Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Health Care

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Wave Life Sciences to Present at Jefferies London Healthcare Conference

Wave Life Sciences to Present at Upcoming Investor Conferences

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Comments

WAVE Life Sciences

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga